A Phase II Evaluation of AZD6244 (NSC 748727, IND 77782) in the Treatment of Recurrent or Persistent Endometrial Carcinoma.

Trial Profile

A Phase II Evaluation of AZD6244 (NSC 748727, IND 77782) in the Treatment of Recurrent or Persistent Endometrial Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 May 2016

At a glance

  • Drugs Selumetinib (Primary)
  • Indications Adenocarcinoma; Endometrial cancer; Squamous cell cancer
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 10 Apr 2013 Planned End Date changed from 1 Jun 2010 to 1 Oct 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top